Discovery of core-structurally novel PTP1B inhibitors with specific selectivity containing oxindole-fused spirotetrahydrofurochroman by one-pot reaction

详细信息    查看全文

• 作者：Suzhen Dong^a ; ^{szdong@brain.ecnu.edu.cn} ; Yubing Lei^a ; ^{leiyubing@163.com} ; Shikun Jia^a ; ^{jiashikun2009@163.com} ; Lixin Gao^b ; ^{lxgao@mail.shcnc.ac.cn} ; Jia Li^b ; ^{jli@mail.shcnc.ac.cn} ; Tong Zhu^a ; ^{tzhu@lps.ecnu.edu.cn} ; Shunying Liu^a ; ^{syliu@sist.ecnu.edu.cn} ; Wenhao Hu^a ; ^{whu@chem.ecnu.edu.cn}
• 关键词：PTP1B inhibitor ; New structure ; Oxindole ; Polycycle ; Spirotetrahydrofurochroman
• 刊名：Bioorganic & Medicinal Chemistry Letters
• 出版年：2017
• 出版时间：15 February 2017
• 年：2017
• 卷：27
• 期：4
• 页码：1105-1108
• 全文大小：758 K
• 卷排序：27

文摘

Protein tyrosine phosphatase 1B (PTP1B) has been proposed to be an ideal target for treatment of type II diabetes and obesity. However, no druggable PTP1B inhibitor has been established and there is still an urgent demand for the development of structurally novel PTPIB inhibitor. Herein, we reported core-structurally novel PTP1B inhibitors with low micromole-ranged inhibitory activity by one-pot reaction from simple starting materials. Further studies demonstrated some of these active compounds had a specific selectivity over other PTPs. The structure and activity relationship was also described. The best active and selective compound 5e inhibited PTP1B activity with an IC50 of 4.53 μM. Molecular docking analysis further demonstrated that compound 5e bound to the active pocket of PTP1B. The results might provide some insights for further development of new drugs for type II diabetes and obesity.